CN112933201A - 一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 - Google Patents
一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN112933201A CN112933201A CN202110318766.4A CN202110318766A CN112933201A CN 112933201 A CN112933201 A CN 112933201A CN 202110318766 A CN202110318766 A CN 202110318766A CN 112933201 A CN112933201 A CN 112933201A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- prepared
- diabetic nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 44
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 15
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 14
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 12
- 239000006002 Pepper Substances 0.000 claims abstract description 12
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 12
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 12
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 12
- 241000218989 Trichosanthes Species 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 241000382455 Angelica sinensis Species 0.000 claims description 15
- 241000045403 Astragalus propinquus Species 0.000 claims description 13
- 241001506371 Kadsura Species 0.000 claims description 11
- 241000722363 Piper Species 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 210000002700 urine Anatomy 0.000 abstract description 14
- 244000164480 Curcuma aromatica Species 0.000 abstract description 13
- 235000014375 Curcuma Nutrition 0.000 abstract description 12
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 12
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 12
- 235000019509 white turmeric Nutrition 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 241000908494 Dioscorea nipponica Species 0.000 abstract description 8
- 235000017008 Dioscorea nipponica Nutrition 0.000 abstract description 8
- 229940109239 creatinine Drugs 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 241000218206 Ranunculus Species 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 238000001914 filtration Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 201000001474 proteinuria Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008517 radix Trichosanthis Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000172774 Ranunculus ternatus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 241000963390 Curcuma wenyujin Species 0.000 description 2
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 241000729196 Lycopus lucidus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000534014 Piper kadsura Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241001063882 Smilax moranensis Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000975594 Trichosanthes rosthornii Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940082094 irbesartan 150 mg Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- -1 qi-tonifying Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种用于治疗糖尿病肾病的中药组合物，包括生黄芪5‑30份，党参5‑20份，制山萸肉5‑20份，泽兰5‑20份，泽泻5‑20份，猫爪草5‑30份，土茯苓10‑40份，海风藤5‑20份，穿山龙5‑20份，天花粉5‑20份，当归5‑20份，莪术5‑20份。本发明还提供了采用所述中药组合物制成的中药制剂及其制备方法。本发明中药组合物君臣佐使俱全，配伍严谨，相辅相成，具有固肾疏风，泄浊和络之功，对改善糖尿病肾病临床证候有显著效果，可降低糖尿病肾病患者的血肌酐、尿素氮及尿蛋白，具有良好的肾脏保护作用，有良好的应用前景。
Description
技术领域
本发明属于医药领域，具体涉及一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法。
背景技术
糖尿病肾病(diabetic nephropathy,DN)是常见的1型和2型糖尿病的慢性并 发症，临床以慢性高血糖、蛋白尿和进行性肾功能损害为主要表现，具有很高的致残 率。糖尿病肾病的发病机制尚未阐述明确，目前认为遗传因素、血流动力学改变、炎 性细胞浸润、糖代谢紊乱及组织缺氧均能导致糖尿病肾病。近年来糖尿病肾病在我国 的发病率不断上升，目前已成为终末期肾脏病的主要原因，仅次于肾小球肾炎。而慢 性肾脏病能导致心血管事件的发生，慢性肾脏病患者的医疗费用是非慢性肾脏病患者 的1.8倍，为患者个人及社会造成了较为沉重的经济负担。
目前糖尿病肾病尚无特效治疗方法，治疗上以控制血糖、血压、血脂及减少蛋白尿为主要原则，并无有效手段阻止DN病情进展。目前血管紧张素转换酶抑制剂(ACEI) 或血管紧张素受体拮抗剂(ARB)为治疗DN首选药，有新的研究表明，盐皮质激素受 体阻断剂(MRB)联合ACEI或ARB使能协助减轻蛋白尿。新型降糖药钠-葡萄糖协同 转运蛋白2(SGLT2)抑制剂，如依帕列净、达格列净等能减少蛋白尿病，减少复合肾 脏结果的发生。GLP-1激动剂对蛋白尿也有有利影响，利拉鲁肽能减少蛋白尿的剂量 依赖性。但上述治疗仍存在局限性及不良反应，治疗DN仍需寻找更有效的治疗方式。
糖尿病的病机以阴虚为本，燥热偏盛，古人多采用上、中、下三消辨证论治。糖 尿病肾病辨证分型和治疗现在没有统一的观点，现代研究表明部分单味药及其提取物 如黄芪、黄精多糖、黄连素等能延缓糖尿病肾病进展，中药复方如益气解毒化瘀小复 方中药、济生肾气丸、肾消汤等可通过不同机制延缓糖尿病肾病的进程。但已上市的 中成药如消渴丸、玉泉丸等均侧重于养阴清热，益气生津，对糖尿病肾病相关证候的 针对性较差，疗效需进一步提高。
发明内容
本发明在于克服现有技术的不足，提供一种用于治疗糖尿病肾病的中药组合物及采用该中药组合物制备而成的中药制剂，显著改善糖尿病肾病临床证候，降低糖尿病 肾病患者的血肌酐、尿素氮及尿蛋白，具有良好的肾脏保护作用。
本发明提供一种用于治疗糖尿病肾病的中药组合物，所述中药组合物由下列重量份数的中药制成：生黄芪5-30份，党参5-20份，制山萸肉5-20份，泽兰5-20份， 泽泻5-20份，猫爪草5-30份，土茯苓10-40份，海风藤5-20份，穿山龙5-20份， 天花粉5-20份，当归5-20份，莪术5-20份。
所述的中药组合物由下列重量份数的中药制成：生黄芪15-30份，党参10-20份，制山萸肉8-20份，泽兰8-20份，泽泻5-20份，猫爪草15-30份，土茯苓20-40份， 海风藤8-20份，穿山龙10-20份，天花粉10-20份，当归8-20份，莪术8-20份。
所述的中药组合物由下列重量份数的中药制成：生黄芪30份，党参15份，制山 萸肉10份，泽兰12份，泽泻10份，猫爪草30份，土茯苓40份，海风藤12份，穿 山龙15份，天花粉15份，当归12份，莪术10份。
所述的中药组合物，制备方法：采用水提法进行提取，制备，即得。
具体水提法为：取中药原料，加水8-16倍(重量)，煎煮1小时，过滤，滤液备 用；滤渣再加上8-16倍(重量)水，煎煮1小时，过滤，弃去滤渣，合并前次滤液， 浓缩，干燥，制成丸剂、片剂、胶囊剂、液体制剂等。
所述的中药组合物，中药原料提取后添加药学上可接受的辅料制备成中药制剂，剂型为丸剂、片剂、胶囊剂、颗粒剂、软胶囊剂、口服液中的一种。
所述的中药组合物在制备治疗糖尿病肾病药物中的应用。
生黄芪，为豆科植物蒙古黄芪(Astragalus mongholicus Bunge)的干燥根。主 产于中国的内蒙古、山西、黑龙江等地。黄芪性微温,具有补气升阳、固表止汗、托 毒生肌之功效。主治气血虚弱、自汗、久泻脱肛、子宫脱垂、肾炎浮肿、蛋白尿、糖 尿病、慢性溃疡等症。近代研究表明其提取物黄芪甲苷具有增强免疫***、抗氧化、 延缓衰老、改善心功能状态、抗病毒、抗癌等功效。
党参，为桔梗科党参属(Codonopsis pilosula(Franch.)Nannf.)，产地中国 北方海拔1560-3100米的山地林边及灌丛中。性平，味甘，具有补中益气、止渴、健 脾益肺，养血生津的功效，主治治脾胃虚弱，气血两亏，体倦无力，食少，口渴，久 泻，脱肛。近代研究表明其主要成分多糖有增强机体免疫力、抗衰老、降血糖等多种 作用。
制山萸肉，为山茱萸科植物山茱萸(Cornus officinalis Sieb.et Zucc.)蒸 透去内核晒干而来，分布于山西、江苏、浙江、安徽、江西、山东、河南、湖南、四 川、陕西、甘肃等地。酸、涩、微温，入肝、肾经。具有补益肝肾，收涩固脱之功效。 常用于眩晕耳鸣，腰膝酸痛，阳痿遗精，遗尿尿频，崩漏带下，大汗虚脱，内热消渴。 现代医学研究表明，山茱萸具有增强免疫***功能、抗炎抑菌、降血糖、抗休克、抗 氧化、抗肿瘤等作用。
泽兰，为唇形科植物毛叶地瓜儿苗(Lycopus lucidus Turcz.vat.hirtus Regel)的干燥地上部分。分布于我国大部分地区。苦、辛，微温。归肝、脾经。具有活血调 经，祛瘀消痈，利水消肿之功效。用于***，经闭，痛经，产后瘀血腹痛，疮痈 肿毒，水肿腹水。现代研究表明泽兰可通过促进HGF及VEGF表达，从而改善肾间质 纤维化，延缓慢性肾脏病的进展。
泽泻，为泽泻科植物泽泻(Alisma orientalis(Sam.)Juzep.)的干燥块茎。甘，寒。归肾、膀胱经，利小便，清湿热，主治小便不利，水肿胀满，泄泻尿少，痰饮眩 晕，热淋涩痛。现代研究表明泽泻水提液能明显抑制乙二醇与活性维生素D3诱导的 大鼠实验性肾结石的形成。
猫爪草，为毛茛科植物小毛茛(Ranunculus ternatus Thunb.)的干燥块根。分 布于广西、台湾、江苏、浙江、江西、湖南、安徽、湖北、河南等地。味甘、辛，性 温。归肝、肺经。具有化痰散结，解毒消肿之功效。常用于瘰疬痰核，疔疮肿毒，蛇 虫咬伤。现代研究表明复方猫爪草水提物有抗炎症作用。
土茯苓，为双子叶植物药百合科植物光叶菝葜的干燥根茎(Glabrous GreenbrierRhizome)。味甘、淡，性平，有解毒，除湿，利关节的功效。主治梅毒，淋浊，筋骨 挛痛，脚气，疔疗疮，痈肿，瘰疬。现代研究表明土茯苓有较好的免疫及抗炎功效。
海风藤，为胡椒科植物风藤(Piper kadsura(Choisy)0hwi)的干燥藤茎，味辛、苦，性微温，归肝经。有祛风湿，通经络，止痹痛功效，主治风寒湿痹，肢节疼痛， 筋脉拘挛，屈伸不利。其有效成分胡椒酮有抗炎作用，风藤烯酮可拮抗血小板激活因 子引起的人中性粒细胞聚集和脱颗粒反应，还可阻断激活因子、组胺、缓激肽昕致的 大鼠皮肤血管通透性增强反应
穿山龙，为薯蓣植物穿龙薯蓣Dioscorea nipponica Makino的干燥根茎，主要 分布于辽宁、吉林、黑龙江、河北、内蒙古等地。味甘、苦，性温，归肝，肾、肺经。 有祛风除湿，舒筋通络，活血止痛，止咳平喘的作用，用于风湿痹病，关节麻木，跌 扑损伤，闪腰岔气，咳嗽气喘。研究表明其有效成分总皂甙能显著降低兔血胆甾醇及 血压，延缓心率、增强心收缩振幅、增加尿量、降低β/α脂蛋白比例，改善冠状循 环。
天花粉，为葫芦科植物栝楼或双边栝楼的干燥根。分布于河南等地。味甘、微苦，微寒，归肺、胃经，有清热泻火，生津止渴，消肿排脓的功效，主治热病烦渴，肺热 燥咳，内热消渴，疮疡肿毒。研究表明天花粉分离出的5种聚糖成分能使小鼠血糖下 降。
当归，为伞形科植物当归(Angelica sinensis(Oliv.)Diels)的干燥根。主产 甘肃东南部，以岷县产量多，质量好，其次为云南、四川、陕西、湖北等省。味甘、 辛，性温，归肝、心、脾经。具有补血活血，调经止痛，润肠通便之功效。常用于血 虚萎黄，眩晕心悸，***，经闭痛经，虚寒腹痛，风湿痹痛，跌扑损伤，痈疽疮 疡，肠燥便秘。酒当归活血通经。用于经闭痛经，风湿痹痛，跌扑损伤。其有效成分 阿魏酸有降血脂作用。
莪术，为姜科植物莪术(Curcuma aeruginosa Roxb.[C.zedoaria non Rosc.])、广西莪术(Curcuma kwangsiensis S.G.Lee et C.F.Liang)和温郁金(Curcuma wenyujinY.H.Chen et C.Ling)的根茎，分布于广东、广西、四川、云南等地； 味辛、苦，性温，归肝、脾经。具有行气破血，消积止痛之功效。常用于血气心痛， 饮食积滞，脘腹胀痛，血滞经闭，痛经，癓瘕痞块，跌打损伤。现代研究表明莪术对 肝肾均有保护作用，且其成分温郁金挥发油有一定抗炎作用。
本发明中的中药组合物组分包括生黄芪，党参，制山萸肉，泽兰，泽泻，猫爪草， 土茯苓，海风藤，穿山龙，天花粉，当归，莪术。其中生黄芪益气固表，利水消肿为 君药，党参、山萸肉助生黄芪补益肾气为臣药，泽兰、泽泻、猫爪草、天花粉、土 茯苓。清热利湿，解毒泄浊，海风藤、穿山龙祛风湿，通经络为佐药，莪术、当归活 血化瘀和络为使药，诸药合用共达固肾疏风泄浊和络之功，本发明中药组合物君臣佐 使俱全，配伍严谨，相辅相成，具有固肾疏风，泄浊和络之功，对改善糖尿病肾病临 床症候非常显著，可降低糖尿病肾病患者血肌酐、尿素氮及尿蛋白，具有良好的保护 肾脏作用，具有良好的应用前景。
具体实施方式
以下结合实例对本发明作进一步的描述，实施例仅用于对本发明进行说明，并不构成对权利要求范围的限制，本领域技术人员可以想到的其他替代手段，均在本发明 权利要求范围内。
实施例1：取生黄芪5g，党参20g，制山萸肉5g，泽兰20g，泽泻5g，猫爪草 30g，土茯苓10g，海风藤20g，穿山龙5g，天花粉20g，当归5g，莪术20g，加药材 重量16倍量的水，煎煮1小时，过滤，药渣再加药材重量8倍量的水，煎煮1小时， 合并两次次水煎液，过滤，将滤液浓缩，真空干燥，得浸膏干粉，加糊精，以80％乙 醇湿法制颗粒，湿颗粒在60℃干燥，即得颗粒剂。
实施例2：取生黄芪30g，党参5g，制山萸肉20g，泽兰5g，泽泻20g，猫爪草 5g，土茯苓40g，海风藤5g，穿山龙20g，天花粉5g，当归20g，莪术5g，加药材重 量16倍量的水，煎煮1小时，过滤，药渣再加药材重量8倍量的水，煎煮1小时， 合并两次水煎液，过滤，将滤液浓缩，真空干燥，得浸膏干粉，加淀粉，制颗粒，压 片，即得片剂。
实施例3：取生黄芪30g，党参15g，制山萸肉10g，泽兰12g，泽泻10g，猫爪 草30g，土茯苓40g，海风藤12g，穿山龙15g，天花粉15g，当归12g，莪术10g，加 药材重量16倍量的水，煎煮1小时，过滤，药渣再加药材重量8倍量的水，煎煮1 小时，合并两次次煎液，过滤，将滤液浓缩，喷雾干燥，得浸膏干粉，加糊精，以制 颗粒，干燥，罐胶囊，即得胶囊剂。
实施例4：取生黄芪30g，党参15g，制山萸肉10g，泽兰12g，泽泻10g，猫爪 草30g，土茯苓40g，海风藤12g，穿山龙15g，天花粉15g，当归12g，莪术10g，加 药材重量16倍量的水，煎煮1小时，过滤，药渣再加药材重量8倍量的水，煎煮1 小时，合并两次水煎液，过滤，将滤液浓缩，制备成口服液剂。
实施例5：取生黄芪30g，党参15g，制山萸肉10g，泽兰12g，泽泻10g，猫爪 草30g，土茯苓40g，海风藤12g，穿山龙15g，天花粉15g，当归12g，莪术10g，加 药材重量16倍量的水，煎煮1小时，过滤，药渣再加药材重量8倍量的水，煎煮1 小时，合并两次次煎液，过滤，将滤液浓缩，喷雾干燥，得浸膏干粉，加辅料，制备 成丸剂。
实施例6：本发明治疗糖尿病肾病的临床观察
1、病例来源：以南京市中医院2018年8月至2020年3月肾病科专科门诊就诊 或住院收治的80例糖尿病肾病患者，治疗组入组患者均符合肾虚湿浊血瘀证，按随 机对照原则将符合纳入标准的患者分为治疗组、对照组，每组40例。
2、糖尿病肾病诊断标准：参照中华医学会内分泌学分会颁发的《中国成人糖尿 病肾脏病临床诊断专家共识2016年版》及改善全球肾脏病预后组织KDIGO颁布的《CKD 评估与管理临床实践指南2012》的糖尿病肾病诊断标准，并按Mogensen分期标准， 属III、IV期DN为观察对象。具体为：①有确切的糖尿病史；②有眼底视网膜病变； ③尿微量白蛋白定量>30mg/24h或尿白蛋白/尿肌酐>30mg/mmol。④eGFR>10ml/min。
3、治疗分组方法：入选前通过限制蛋白摄入、给予优质低蛋白饮食、控制血糖、 降压等治疗，达到基本体征平稳，符合入选条件的病例进入本试验。入选病例按照1： 1随机分成治疗组和对照组。本研究中治疗组脱落2例，治疗组38例，对照组40 例。
(1)基础治疗：对患者进行相关基础知识宣教；低盐低脂优质低蛋白饮食；给 予口服降糖药或胰岛素控制血糖，用量随具体病情而定，保证血糖达标同时避免低血 糖发生，使空腹血糖≤7.1mmol/L，餐后2h血糖<11.1mmol/L，糖化血红蛋白 <7％。
(2)对照组治疗：在基础治疗同时，根据血压情况，高血压者给予厄贝沙坦 150mg，每日1次。血肌酐>265umol/l的患者选择非ACEI、ARB类降压药物控制血压。
(3)治疗组治疗：在基础治疗中降压选择非ACEI、ARB类药物。并给予实施例 4制成的口服液剂。早晚2次分服，每次服用20ml，疗程8周。
表1治疗前后Scr、BUN、GFR比较
注：与本组治疗前采用配对样本t检验比较，**P＜0.01。与对照组治疗后组间 比较，ΔP＜0.05，ΔΔP＜0.01。
表2治疗前后ACR、MAlb的比较
注：与本组治疗前对比较，*P＜0.05，**P＜0.01。与对照组治疗后组间比较， ΔP＜0.05。
上述临床实验显示，本发明能降低Scr(μmol/L)、BUN(mmol/L)、ACR(mg/gCr)、MAlb(mg/L)，升高GFR(ml/min*1.73m2)，与对照组比较具有显著性差异，说明本发明 对糖尿病肾病具有良好的治疗效果。
实施例7：本发明药效学实验
1、仪器与材料
1.1主要仪器：HEA-230血糖仪(日本OMRON公司)，血糖试纸(日本OMRON公 司)，5415R型离心机(德国Eppendorf公司)，Sartorius电子天平(赛多利斯科学 仪器(北京)有限公司)，日立OLYMPUS自动生化分析仪(型号7600，南京三和公司)。
1.2试剂：链脲佐菌素(STZ，SIGMA公司)；实施例4制备得到的口服液剂。
1.3实验动物：60只健康雄性Sprague-Dawley(SD)大鼠，清洁级，4-6周龄， 体重约140-220g，购自南通大学，许可证号：SYXK(苏)2017-0040。适应性喂养一 周，无不良反应即进入实验。
2、实验方法
2.1造模：50只SD大鼠按随机数字表分组，其中正常组(N组)10只，造模组 50只，适应性喂养7天后，禁食12h，称重后，制备糖尿病肾病模型，模型组按55mg/kg 的剂量一次性左侧腹腔注射1％链脲佐菌素(STZ)溶液，正常组(N组)用等量生理 盐水左侧腹腔注射，各组均予标准饮食，定期更换垫料，消毒笼具。STZ溶液注射造 模后72h连续测3天随机血糖，血糖值＞16.7mmol/L为糖尿病(DM)模型制备成功, 未达标者重复予STZ溶液55mg/kg左侧腹腔注射1次，5天后复测血糖达标者进入后 续糖尿病肾病(DN)造模。DM造模成功后的大鼠喂养1周后测随机血糖＞16.7mmol/L， 尿量为正常组(N组)的1.5倍及以上，24h尿蛋白为正常组(N组)的1.5倍及以上， 则为DN模型制备成功，指标未达标准的造模大鼠予以剔除。
2.2分组及给药：DN成模大鼠40只随机分为模型组(DN组)10只、中药复方 低剂量组10只、中药复方中剂量组(GSM组)10只、中药复方高剂量组(GSH组)10 只。大鼠给药剂量按动物与人体每公斤体质量折算(人的6.25倍)，中药复方组低中 高剂量组均采用实施例1制得药物成分。N组、DN组均予0.1ml/10g生理盐水灌胃， 中药复方组分别按试验药物低、中、高浓度(分别为10.99、21.98、43.96g/kg)给 药，给药体积均为0.1ml/10g，每天给药1次，连续给药6周。
2.3观测指标：血糖：造模成功后第0天、21天、42天分别用HEA-230血糖仪 检测大鼠随机血糖。24小时尿蛋白定量：成模后及药物干预结束后分别用代谢笼收集24小时尿液，记录尿量，放免法测定24小时尿蛋白含量。肾功能：血样于南京市中 医院检验科，通过OLYMPUS自动生化分析仪检测Scr、BUN。肾脏病理组织学观察：大 鼠麻醉后脱颈椎处死，取右肾，去除被膜，用生理盐水灌洗肾脏血管以除去血液，滤 纸干燥，沿矢状正中线切开，将其1/2置入4％多聚甲醛固定液，48小时候常规石蜡 包埋，连续4um切片，HE染色，光镜下观察肾脏病理组织学变化。
2.4统计学处理：采用SPSS26.0软件进行统计学分析。计量资料以(X±S)表 示，两两比较采用t检验，多组比较采用单因素方差分析。P＜0.05为差异有统计学 意义。
3、实验结果
3.1各组大鼠空腹血糖比较(表3)
表3各组大鼠随机血糖变化比较(mmol/L)(X±S)(n＝10)
注：与正常对照组相比，ΔP<0.01，与模型组相比，※P<0.05
与正常对照组比较，其余各组小鼠血糖显著升高(P<0.01)，各给药组血糖无显 著差异(P>0.05)。随时间延长，各给药组血糖均较模型组下降，差异有统计学意义 (P<0.05)。
3.2各组大鼠24小时尿蛋白情况(表4)
表4各组大鼠24小时尿蛋白比较(mg/24h)(X±S)(n＝10)
注：与正常对照组比较，ΔP<0.01，与模型组比较各组尿蛋白定量均有改善， 以受试中药高剂量组减轻最明显，#P<0.01。
3.3各组大鼠血清Scr、BUN水平比较(表5)
表5各组大鼠血清Scr、BUN水平(X±S)(n＝10)
注：与正常组相比，#P<0.01,与模型组比较，ΔP<0.05。
3.4各组大鼠肾脏病理积分比较(表6)
表6各组大鼠肾脏病理积分(X±S)(n＝10)
注：与模型组比较，ΔP<0.05。
结论：本发明可有效降低糖尿病肾病大鼠血糖、血肌酐、尿素氮、24小时尿蛋白,并改善肾脏损伤，其疗效与药物剂量有关。
Claims (6)
1.一种用于治疗糖尿病肾病的中药组合物，其特征在于，所述中药组合物由下列重量份数的中药制成：生黄芪5-30份，党参5-20份，制山萸肉5-20份，泽兰5-20份，泽泻5-20份，猫爪草5-30份，土茯苓10-40份，海风藤5-20份，穿山龙5-20份，天花粉5-20份，当归5-20份，莪术5-20份。
2.根据权利要求1中所述的中药组合物，其特征在于，所述中药组合物由下列重量份数的中药制成：生黄芪15-30份，党参10-20份，制山萸肉8-20份，泽兰8-20份，泽泻5-20份，猫爪草15-30份，土茯苓20-40份，海风藤8-20份，穿山龙10-20份，天花粉10-20份，当归8-20份，莪术8-20份。
3.根据权利要求2所述的中药组合物，其特征在于，所述中药组合物由下列重量份数的中药制成：生黄芪30份，党参15份，制山萸肉10份，泽兰12份，泽泻10份，猫爪草30份，土茯苓40份，海风藤12份，穿山龙15份，天花粉15份，当归12份，莪术10份。
4.根据权利要求1-3中任意一项所述的中药组合物，其特征在于，制备方法：采用水提法进行提取，制备，即得。
5.根据权利要求1-3中任意一项所述的中药组合物，其特征在于，中药提取后添加药学上可接受的辅料制备成中药制剂，剂型为丸剂、片剂、胶囊剂、颗粒剂、软胶囊剂、口服液中的一种。
6.根据权利要求1-3中任意一项所述的中药组合物在制备治疗糖尿病肾病药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318766.4A CN112933201A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110318766.4A CN112933201A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112933201A true CN112933201A (zh) | 2021-06-11 |
Family
ID=76226804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110318766.4A Pending CN112933201A (zh) | 2021-03-25 | 2021-03-25 | 一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112933201A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040622A (zh) * | 2022-08-03 | 2022-09-13 | 南京市中医院 | 一种用于治疗糖尿病肾病的中药组合物及制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548997A (zh) * | 2005-10-08 | 2009-10-07 | 河北以岭医药研究院有限公司 | 作用于nei网络的药物在制备治疗血管病变的药物中的应用 |
-
2021
- 2021-03-25 CN CN202110318766.4A patent/CN112933201A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548997A (zh) * | 2005-10-08 | 2009-10-07 | 河北以岭医药研究院有限公司 | 作用于nei网络的药物在制备治疗血管病变的药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| 崔瑛等: "参芪地黄汤联合糖尿病电脑治疗仪治疗早期糖尿病肾病对照观察", 《实用中医内科杂志》 * |
| 施旭辉主编: "《马中夫五十年临证医鉴》", 31 March 2014, 辽宁科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115040622A (zh) * | 2022-08-03 | 2022-09-13 | 南京市中医院 | 一种用于治疗糖尿病肾病的中药组合物及制备方法 |
| CN115040622B (zh) * | 2022-08-03 | 2023-04-25 | 南京市中医院 | 一种用于治疗糖尿病肾病的中药组合物及制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
| CN102343023B (zh) | 药物组合物及其制备方法和用途 | |
| CN104547579A (zh) | 一种治疗高泌乳素血症性***的药物组合物及其应用 | |
| CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
| CN102488743B (zh) | 中药组合物、制备方法及中药制剂 | |
| CN103142842B (zh) | 一种治疗糖尿病的中药 | |
| CN102988675B (zh) | 一种治疗慢性***炎的中药组合物及其制备方法 | |
| CN1618446A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
| CN101053619B (zh) | 一种治疗肺纤维化的药物 | |
| JP2002154979A (ja) | Ｉ型アレルギー用医薬組成物およびその製造方法 | |
| CN101406598B (zh) | 治疗糖尿病的中药组合物及其制备方法 | |
| CN113713039A (zh) | 一种治疗膜性肾病的中药组合物及其应用 | |
| CN103006989B (zh) | 一种治疗糖尿病肾病的药物组合物 | |
| CN112933201A (zh) | 一种用于治疗糖尿病肾病的中药组合物、中药制剂及其制备方法 | |
| CN100522230C (zh) | 一种治疗糖尿病肾病的药物及其制备方法 | |
| CN100518809C (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
| CN105267559B (zh) | 一种治疗糖尿病周围神经病变的药物及其制作方法 | |
| CN104721467B (zh) | 一种治疗糖尿病肾病的中药组合物及其用途 | |
| CN101085121A (zh) | 一种降血糖、降血脂的中药组合物及制法和应用 | |
| CN102114189A (zh) | 一种治疗糖尿病的超微粒中药降糖片 | |
| CN105999058B (zh) | 鬼针草降脂片 | |
| CN105327115B (zh) | 一种防治ⅱ型糖尿病桑黄通泻配方及制备工艺 | |
| CN107007702A (zh) | 一种治疗骨关节病的中药组合物及其制剂 | |
| CN104758705A (zh) | 治疗慢性肾炎的中药组合物及制备方法 | |
| CN105194355A (zh) | 一种治疗原发性高血压的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210611 |